Aardvark Therapeutics

Intangible assets 35/100: ARD‑101 holds Orphan Drug and Rare Pediatric Disease designations in PWS and may qualify for five years of NCE exclusivity if approved, which together could yield meaningful regulatory exclusivity. However, exclusivity is contingent on ultimate approval and does not block different drugs for the same indication.

Switching costs 25/100: If effective, rare‑disease caregivers are loyal, but the presence of an approved alternative reduces stickiness unless ARD‑101 demonstrates superior outcomes or safety. Network effects 0/100: None.

Cost advantages 25/100: Oral, gut‑restricted dosing could be convenient, yet any cost advantage is unclear given an entrenched first mover and premium rare‑disease pricing norms. Efficient scale 30/100: PWS is small and concentrated, but first‑mover Vykat XR already addresses the core need, limiting efficient‑scale benefits for a follower.

Overall moat assessment is modest, pending safety resolution and clinically meaningful differentiation.